Innovent Biologics' SINTBILO® (tafolecimab injection), a PCSK9 monoclonal antibody, achieved over 60% reduction in LDL cholesterol after 12 weeks in a Phase 3 trial involving Chinese patients with non-familial hypercholesterolemia and mixed hyperlipidemia. The drug also significantly improved other lipid markers and showed a favorable safety profile with no serious adverse events. As the first domestically developed PCSK9 antibody in China, SINTBILO® is included in the National Reimbursement Drug List and has benefited over one million patients. Innovent plans to apply for a new indication to expand its use as a convenient first-line treatment for hyperlipidemia in China.
Innovent Biologics' SINTBILO® trial results provide context for health sector activity. For readers following health stocks, 88 of 150 US health-sector stocks rose while 62 fell as of Nov 09, 2026 04:51 WIB. Notable gainers include DFTX at USD 33.27 (+9.58%), RLAY at USD 18.60 (+9.41%), and ELAN at USD 25.74 (+8.75%).
NVIDIA's Board of Directors has started an independent investigation after reports that CEO Jensen Huang was targeted by a foreign intelligence operation. The inquiry, led by independent directors and external counsel, aims to ensure no national secu...
On November 7, whale positions on Hyperliquid reached about $7.57 billion, with short positions totaling approximately $4.126 billion, exceeding long positions by around $680 million. Shorts made up 54.49% of the total positions, while longs accounte...
On November 7, Binance's Bitcoin perpetual futures order book revealed a bid for about 150.16 BTC at $75,943, slightly below the midpoint price of $76,020. Total bids amounted to $51.04 million, while asks were higher at $58.51 million, creating a $7...
David Sacks warns that the AI data center boom could stall by 2028 because of permitting challenges and potential moratoriums in key states. This freeze could disrupt the entire supply chain, affecting chipmakers like NVIDIA and Broadcom, as well as ...
Bitcoin stayed the most-searched cryptocurrency on November 6 despite a slight 0.12% price drop to $75,963. Pearl showed the largest gain among seven listed assets, rising 10.69% to $1.78. Other notable movers included Zcash, Solana, Sui, and Hyperli...
